Events and Presentations

Upcoming Events

There are no upcoming events available at this time.

Past Events

September 28, 2021 at 4:00 PM EDT

Cantor Global Healthcare Virtual Conference

Click here for webcast

September 21, 2021 at 8:30 AM EDT

Stoke Therapeutics MONARCH study in Dravet Syndrome Interim Analysis

Click here for webcast

Supporting Materials

Stoke Therapeutics MONARCH study in Dravet Syndrome Interim Analysis Presentation 4.4 MB

August 12, 2021 at 12:30 PM EDT

Canaccord Genuity 41st Annual Growth Conference

Click here for webcast

August 11, 2021 at 11:30 AM EDT

2021 Wedbush PacGrow Healthcare Virtual Conference

Click here for webcast

May 24, 2021 at 5:00 PM EDT

UBS Global Healthcare Virtual Conference

Click here for webcast

April 15, 2021 at 12:45 PM EDT

20th Annual Needham Virtual Healthcare Conference

Click here for webcast

March 31, 2021 at 2:00 PM EDT

Stifel 3rd Annual CNS Day

Click here for webcast

March 11, 2021 at 3:35 PM EST

Barclays Global Healthcare Conference

Click here for webcast

January 11, 2021 at 4:30 PM EST

39th Annual J.P. Morgan Healthcare Conference

Click here for webcast

December 10, 2020 at 12:45 PM EST

Needham Virtual Epilepsy & Pain - Specialty CNS Therapeutics Conference

Click here for webcast

Corporate Presentation

Corporate Presentation – October 2021

Key Publications

August 26, 2020

Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome

Source

Science Translational Medicine

July 9, 2020

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Source

Nature Communications

Genetic Epilepsies Presentations

December 4, 2020

Observational Study to Investigate Cognition and Other Non-seizure Comorbidities in Children and Adolescents with Dravet Syndrome: Baseline Analysis of the BUTTERFLY Study

Source

AES 2020

December 4, 2020

Reducing the Time to Diagnosis and Increasing the Detection of Individuals with SCN1A-Related Disease Through a No-cost, Sponsored Epilepsy Genetic Testing Program

Source

AES 2020

December 4, 2020

Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study

Source

AES 2020

December 4, 2020

Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome

Source

AES 2020

December 4, 2020

Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome – Oral Presentation

Source

AES 2020

December 8, 2019

TANGO oligonucleotides for the treatment of Dravet Syndrome: Safety, biodistribution and pharmacology in the non-human primate

Source

AES 2019

December 7, 2019

Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a Prevents SUDEP in a mouse model of Dravet Syndrome

Source

AES 2019

Neuro-Ophthalmology Presentations

May 4, 2021

Antisense oligonucleotide mediated increase in OPA1 improves mitochondrial function in fibroblasts derived from patients with autosomal dominant optic atrophy (ADOA)

June 12, 2020

Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for the treatment of autosomal dominant optic atrophy

Source

ARVO 2020

May 12, 2020

POSTER: Antisense oligonucleotide mediated increase of OPA1 expression using TANGO technology for treatment of autosomal dominant optic atrophy

Source

ASGCT 2020

Toolkit

Print Page

Email Alerts

Contact IR

FAQ